Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

levodopa + carbidopa

DUODOPA

levodopa + carbidopa (DUODOPA) is an FDA-listed pharmaceutical active ingredient. Associated with Alphapharm Pty Ltd.

TGA: approved
Patents linked 20
Pipeline programs 121
News articles 0
Drug details — levodopa + carbidopa
Class
—
Route
—
Patents
20
Programs
121
Data quality
0.81
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

levodopa + carbidopa (DUODOPA) is an FDA-listed pharmaceutical active ingredient. Associated with Alphapharm Pty Ltd.

Key facts

INN levodopa + carbidopa
Brand DUODOPA
Originator Alphapharm Pty Ltd

Approval history

Authority Status Date
TGA approved —

Pipeline programs

Browse pipeline Sponsor programs
  1. 116130 Phase 3 · Disc Medicine · Parkinson's disease
  2. 11C-SB207145, 11C-DASB Phase 3 · George Institute for · Parkinson's disease, Prodromal phase of Parkinson's disease
  3. BHV8000-301 Phase 3 · Biohaven Bioscience Ireland · Early Parkinson’s Disease
  4. BIIB122 Phase 3 · Denali Therapeutics · Parkinson Disease
  5. BN42358 Phase 3 · HOFFMANN-LA ROCHE · Early Parkinson's disease
  6. CEP-1347 10mg Phase 3 · Teva Pharma · Parkinson Disease
  7. Dipraglurant Phase 3 · Addex Therapeutics · Parkinson Disease
  8. KW-6500 Phase 3 · Kyowa Kirin International · Parkinson's Disease

Related patents

Browse patents Alphapharm Pty Ltd patent hub

  1. US 12383626

    Polyoxazoline-drug conjugates with novel pharmacokinetic properties

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12383625

    Polyoxazoline-drug conjugates with novel pharmacokinetic properties

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12350253

    Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12319929

    Compositions and methods for the treatment of Parkinson's disease

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12233132

    Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12161755

    Sustained release device for treatment of Parkinson's disease and other disorders

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2024242579

    RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE

    Expires Wed Nov 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12036198

    Dosage forms and therapeutic uses of L-4-chlorokynurenine

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11975056

    AADC polynucleotides for the treatment of Parkinson's disease

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11925689

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2024039256

    RÉGIMES THÉRAPEUTIQUES POUR LA MALADIE DE PARKINSON

    Expires Wed Feb 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11759506

    AADC polynucleotides for the treatment of Parkinson's disease

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2022158991

    TRAITEMENT DE LA DOULEUR ASSOCIÉE À LA MALADIE DE PARKINSON AVEC DE L'OPICAPONE EN COMBINAISON AVEC LA LÉVODOPA

    Expires Wed Jul 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. WO 2022131944

    RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE

    Expires Wed Jun 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. WO 2022081033

    OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

    Expires Wed Apr 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11213588

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11071729

    1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11027000

    AADC polynucleotides for the treatment of Parkinson's disease

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10980758

    Dosage forms and therapeutic uses of L-4-chlorokynurenine

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10864276

    Activated polyoxazolines and conjugates and compositions comprising the same

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is levodopa + carbidopa?

levodopa + carbidopa (DUODOPA) is an FDA-listed pharmaceutical active ingredient. Associated with Alphapharm Pty Ltd.

What is the brand name for levodopa + carbidopa?

DUODOPA is a marketed brand name for levodopa + carbidopa. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.